Key Takeaways The OmniVu Lens System demonstrated stable refractive outcomes and excellent distance, intermediate, and near vision through 36 months post-implantation Patients achieved a continuous range of focus (~5.0 D) with minimal safety interventions The modular, shape-changing lens design may represent a significant advancement in cataract surgery by reducing traditional trade-offs between visual range, stability, and quality Atia Vision has announced positive 36-month outcomes from its first-in-human (FIH) clinical study of the Atia Vision OmniVu Lens System, a modular, shape-changing IOL designed to restore a continuous range of vision following cataract surgery. The data, presented by William F. Wiley, MD, Medical Director of the Cleveland Eye Clinic, at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, was awarded Best Paper of Session. Findings demonstrated sustained visual and refractive performance through 3 years post-implantation, alongside a favorable safety profile. The prospective, multicenter, open-label study enrolled 19 patients (29 eyes), including both binocular (10 subjects) and monocular (9 subjects) implants. At 36 months, patients maintained highly stable refractive outcomes. Mean manifest refraction spherical equivalent (MRSE) remained within ±0.50 diopters throughout the study period, with refractive cylinder also showing long-term stability. Visual acuity results were notably strong: Uncorrected distance vision: -0.11 logMAR (20/16) Best-corrected distance vision: -0.17 logMAR (20/12) Uncorrected intermediate vision: -0.05 logMAR (20/20) Uncorrected near vision: 0.06 logMAR (20/25, J1) Defocus curve testing further demonstrated a continuous range of focus, with patients achieving 20/32 vision or better across approximately 5.0 diopters of defocus. The OmniVu system also showed a strong safety profile. Across all study visits: Only one YAG capsulotomy procedure was required No lens exchanges were reported No refractive enhancements were needed Additionally, early sub-study data indicated contrast sensitivity comparable to monofocal IOLs under mesopic conditions—an important benchmark for presbyopia-correcting lenses, which often face trade-offs in visual quality. “Surgeons have long had to accept trade-offs with presbyopia-correcting lenses,” Dr. Wiley said. “These 36-month data tell a very different story. Continuous focus from far to near, stable lens position, and remarkably low YAG rates sustained over three years is exactly what we need to see. This could be a real turning point for premium cataract surgery.” The OmniVu Lens System features a two-component modular architecture: A fluid-filled, shape-changing base designed to respond to the eye’s natural accommodative mechanisms A front optic tailored to meet the patient’s refractive needs Its capsular bag-filling design aims to preserve the eye’s natural anatomy, promoting stable lens positioning and reducing the risk of posterior capsule opacification (PCO). The OmniVu Lens System has received Investigational Device Exemption (IDE) approval from the FDA, enabling the initiation of a US feasibility clinical study.